Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis.

Literature DB >> 7698710

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis.

Abstract

A 17 year old Asian patient with autoimmune chronic active hepatitis resistant to treatment with high dose corticosteroids and azathioprine was given cyclosporin at a dose of 5 mg/kg/day. Within two weeks of starting the cyclosporin treatment a favourable clinical and biochemical response was obtained and by one month serum aminotransferase activities were within normal limits. An attempted reduction in the daily dose of cyclosporin resulted in a relapse of the patient's disease. Remission was again attained by returning the dose of cyclosporin to 5 mg/kg/day. No significant side effects of the treatment have been shown. Cyclosporin seems to have a role in the treatment of corticosteroid resistant autoimmune chronic active hepatitis and its further evaluation is warranted.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 7698710 PMCID： PMC1382466 DOI： 10.1136/gut.36.3.459

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

21 in total

1. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors: G Feutren; M J Mihatsch
Journal: N Engl J Med Date: 1992-06-18 Impact factor: 91.245

2. Treatment of chronic active hepatitis. An analysis of three controlled trials.

Authors: E C Wright; L B Seeff; P D Berk; A Jones; P H Plotz
Journal: Gastroenterology Date: 1977-12 Impact factor: 22.682

3. Controlled trial of prednisone and azathioprine in active chronic hepatitis.

Authors: I M Murray-Lyon; R B Stern; R Williams
Journal: Lancet Date: 1973-04-07 Impact factor: 79.321

4. Long-term results of therapy in patients with chronic liver disease associated with hypergammaglobulinemia.

Authors: A R Page; R A Good; B Pollara
Journal: Am J Med Date: 1969-11 Impact factor: 4.965

5. Autosensitization of lymphocytes against thymus reticulum cells.

Authors: I R Cohen; H Wekerle
Journal: Science Date: 1972-06-23 Impact factor: 47.728

6. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors: W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal: Gut Date: 1975-11 Impact factor: 23.059

7. Natural history, clinical features, and treatment of autoimmune hepatitis.

Authors: A J Czaja
Journal: Semin Liver Dis Date: 1984-02 Impact factor: 6.115

Review 8. Adverse effects of azathioprine.

Authors: D H Lawson; G E Lovatt; C S Gurton; R C Hennings
Journal: Adverse Drug React Acute Poisoning Rev Date: 1984

9. Cyclosporine-associated chronic nephropathy.

Authors: B D Myers; J Ross; L Newton; J Luetscher; M Perlroth
Journal: N Engl J Med Date: 1984-09-13 Impact factor: 91.245

10. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors: D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal: Eur J Immunol Date: 1981-08 Impact factor: 5.532

17 in total

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis.

1. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

2. Treatment of chronic active hepatitis. An analysis of three controlled trials.

3. Controlled trial of prednisone and azathioprine in active chronic hepatitis.

4. Long-term results of therapy in patients with chronic liver disease associated with hypergammaglobulinemia.

5. Autosensitization of lymphocytes against thymus reticulum cells.

6. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

7. Natural history, clinical features, and treatment of autoimmune hepatitis.

Review 8. Adverse effects of azathioprine.

9. Cyclosporine-associated chronic nephropathy.

10. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Review 1. The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

2. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis.

Review 3. Difficult treatment decisions in autoimmune hepatitis.

Review 4. Autoimmune hepatitis: focusing on treatments other than steroids.

Review 5. Acute and acute severe (fulminant) autoimmune hepatitis.

Review 6. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

7. Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Review 8. Drug therapy in the management of type 1 autoimmune hepatitis.

9. The use of budesonide in the treatment of autoimmune hepatitis in Canada.

Review 10. Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids.